Why the study?
Does antihypertensive drug therapy reduce premature cardiovascular deaths, myocardial infarctions, and strokes in U.S. adults age 40 and older?
Does antihypertensive drug therapy reduce premature cardiovascular deaths, myocardial infarctions, and strokes in U.S. adults age 40 and older?
Antihypertensive therapy has provided substantial public health and economic benefits in the U.S., preventing tens of thousands of cardiovascular deaths and hundreds of thousands of hospitalizations annually.
Answers are grounded in this paper and cite their sources.
Supports broad antihypertensive use in adults ≥40; confirms RCT benefits at population scale with strong cost-effectiveness.
We estimated what the improved treatment of high blood pressure with anithypertensive drug therapy has contributed to U.S. public health, in terms of reductions in excess premature deaths from cardiovascular disease, myocardial infarctions, and strokes. Using national survey data to estimate blood pressures in the absence of antihypertensive therapy and comparing them with blood pressures actually observed in 1999-00, we inferred the impact of antihypertensive therapy on blood pressure. Using risk equations from the Framingham Heart Study, we estimated the impact of lowered blood pressures on the risk and number of myocardial infarctions and strokes (2002) and deaths (2001). Assigning a monetary value from the literature to the improvement in overall life expectancy related to antihypertensive therapy, we compared it to average spending on antihypertensives. Antihypertensive therapy has had a major impact on U.S. public health. In the absence of antihypertensives, 1999–00 blood pressures for adults age 40 + would have been 10 to 13 percent higher, and 86000 excess premature deaths from cardiovascular disease (2001), and 833,000 hospital discharges for stroke and myocardial infarction (2002) would have occurred. Treatment has generated a benefit-to-cost ratio of at least 6:1, but much more can be achieved.
No takes yet. Share an insight, caveat, or question.
Long et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: